Genetic Signatures appoints interim managing director

Grafa
Genetic Signatures appoints interim managing director
Genetic Signatures appoints interim managing director
Mahathir Bayena
Written by Mahathir Bayena
Share

Genetic Signatures (ASX:GSS) has appointed Non-Executive Director Anne Lockwood as its interim Managing Director to fortify its leadership during a strategic transition period.

Bringing over 30 years of expertise in finance and risk management—including high-level roles at EY and as CFO of Integral Diagnostics—Lockwood is tasked with overseeing financial discipline and corporate governance for an initial six-month term.

She will work alongside the newly appointed CEO, Maria Halasz, a move the Board indicates will streamline costs and ensure operational continuity following the recent departures of the former CEO and CFO.

Consequently, the search for a permanent CFO has been deferred while Lockwood handles the dual priorities of financial oversight and strategic execution.

At the time of reporting, Genetic Signatures' share price was $0.15.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.